Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Oct;40(4):704-715.
doi: 10.1002/hon.3031. Epub 2022 Jun 1.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Antonella Bruzzese  1 , Daniele Derudas  2 , Monica Galli  3 , Enrica Antonia Martino  1 , Stefano Rocco  4 , Concetta Conticello  5 , Catello Califano  6 , Nicola Giuliani  7 , Silvia Mangiacavalli  8 , Giuliana Farina  9 , Alessandra Lombardo  10 , Marino Brunori  11 , Elena Rossi  12 , Elisabetta Antonioli  13 , Roberto Ria  14 , Renato Zambello  15 , Nicola Di Renzo  16 , Giuseppe Mele  17 , Gianpaolo Marcacci  18 , Giuseppe Pietrantuono  19 , Gaetano Palumbo  20 , Nicola Cascavilla  21 , Claudio Cerchione  22 , Angelo Belotti  23 , Clelia Criscuolo  24 , Giuseppina Uccello  25 , Paola Curci  26 , Ernesto Vigna  1 , Francesco Mendicino  1 , Enrico Iaccino  27 , Selena Mimmi  27 , Cirino Botta  1   28 , Donatella Vincelli  29 , Nicola Sgherza  26 , Angela Bonalumi  30 , Luca Cupelli  31 , Raffaella Stocchi  32 , Massimo Martino  33 , Stelvio Ballanti  34 , Dominella Gangemi  35 , Alfredo Gagliardi  36 , Barbara Gamberi  37 , Alessandra Pompa  38 , Giovanni Tripepi  39 , Ferdinando Frigeri  9 , Ugo Consoli  27 , Sara Bringhen  40 , Elena Zamagni  41 , Francesca Patriarca  32 , Valerio De Stefano  12 , Francesco Di Raimondo  5 , Salvatore Palmieri  4 , Maria Teresa Petrucci  42 , Massimo Offidani  43 , Pellegrino Musto  26   44 , Mario Boccadoro  40 , Michele Cavo  41 , Antonino Neri  45 , Fortunato Morabito  46   47 , Massimo Gentile  1
Affiliations
Free article
Multicenter Study

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Antonella Bruzzese et al. Hematol Oncol. 2022 Oct.
Free article

Abstract

The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with International Staging System stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups.

Keywords: dexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapy.

PubMed Disclaimer

References

REFERENCES

    1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128. https://doi.org/10.1038/leu.2013.313
    1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520. https://doi.org/10.1182/blood-2007-10-116129
    1. Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443-2448. https://doi.org/10.1038/leu.2017.138
    1. Durer C, Durer S, Lee S, et al. Treatment of relapsed multiple myeloma: evidence-based recommendations. Blood Rev. 2019;39:100616. https://doi.org/10.1016/j.blre.2019.100616
    1. Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841-1849. https://doi.org/10.1007/s00262-013-1493-8

Publication types

MeSH terms